Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473720 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00473720 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 15 participants.
The verdict
NCT00473720, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase I dose escalating study of oral satraplatin in combination with Abraxane administered weekly for three out of every four weeks in patients with advanced solid cancers.
Interventions
- DRUG Abraxane
- DRUG Satraplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00473720
The ClinicalTrials.gov registry entry for NCT00473720 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abraxane is the first listed.
NCT00473720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00473720 about?
NCT00473720 is a clinical study titled "Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers". This is a phase I dose escalating study of oral satraplatin in combination with Abraxane administered weekly for three out of every four weeks in patients with advanced solid cancers.
What is the current status of trial NCT00473720?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00473720?
The interventions under investigation include: Abraxane (DRUG), Satraplatin (DRUG).
Who is sponsoring clinical trial NCT00473720?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.